Related Experiment Videos
Toxicity and teratogenicity studies with the hypolipidemic drug RMI 14,514 in rats
Summary
The hypolipidemic drug RMI 14,514 showed no significant toxicity in rats, with only mild liver lipid accumulation at high doses. It did not cause birth defects or developmental issues in offspring, despite reducing plasma cholesterol.
Area of Science:
- Pharmacology
- Toxicology
- Drug Development
Background:
- RMI 14,514 is a hypolipidemic drug.
- Understanding its safety profile is crucial for potential therapeutic use.
Purpose of the Study:
- To evaluate the chronic toxicity, developmental toxicity, and metabolic effects of RMI 14,514 in rats.
Main Methods:
- Chronic toxicity study (6 months) with oral doses.
- Developmental toxicity studies (in utero and post-natal exposure).
- Analysis of plasma and tissue lipids, including erythrocyte membrane integrity.
Main Results:
- High doses (300 mg/kg/day) caused growth retardation and mild hepatic lipid accumulation, reversible after drug withdrawal.
- No teratogenic effects or significant adverse developmental/behavioral outcomes were observed.
- RMI 14,514 reduced plasma cholesterol and fatty acids, and erythrocyte lipids, without compromising membrane integrity.
Conclusions:
- RMI 14,514 demonstrates a low toxicity profile in rats.
- It is not teratogenic and has minimal developmental effects.
- The drug's impact on lipids is specific and does not appear to compromise cell membrane function.